Issue 5/2024
Savova, R., Borizanova, A., Krastev, B., Kinova, E., Gudev, A.
Clinc of Cardiology at UMHAT “ Qeen Joanna – ISUL ”, Medical University – Sofia
Prevention of atherosclerotic cardiovascular disease (ASCVD) in a given person should relate to his or her total CV risk: the higher the risk, the more intense the action should be. The new revised concepts of the recommendations of the European Society of Cardiology (ESC) from 2019 are for a more intensive reduction of LDL-cholesterol in all categories of cardiovascular risk. After experiencing an acute coronary syndrome (ACS), patients are at a high risk of suffering from recurrent ischaemic cardiovascular events, especially in the very early phase. Low density lipoprotein-cholesterol (LDL-C) is causally involved in atherosclerosis and a clear, monotonic relationship between pharmacologic LDL-C lowering and a reduction in cardiovascular events post-ACS has been shown, a concept termed „the lower, the better“. Another new one strategy, is the initiation of a combined and highly intensified lipid-lowering therapy in the early phase of ACS, known as „strike early and strike strong“.
Key words: atherosclerotic cardiovascular disease, low-density lipoprotein cholesterol (LDL-C), acute coronary syndrome (ACS), proprotein convertase subtilisin/kexin type 9 – PCSK9 inhibitor, coronary artery disease (CAD), lipid-lowering therapy (LLT), myocardial infarction (MI), European Society of Cardiology (ESC)
Address for correspondence:
Savova, R., Borizanova, A.
Clinc of Cardiology at UMHAT “Qeen Joanna – ISUL”,
Medical University – Sofia
8, Bialo more, Str.
1527, Sofia
e-mail: rumenasavova@gmail.com
borizanowa@abv.bg